Last $15.91 USD
Change Today +0.17 / 1.08%
Volume 1.3M
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

celldex therapeutics inc (CLDX) Snapshot

Open
$15.87
Previous Close
$15.74
Day High
$16.23
Day Low
$15.78
52 Week High
10/2/13 - $38.84
52 Week Low
05/9/14 - $10.76
Market Cap
1.4B
Average Volume 10 Days
2.3M
EPS TTM
$-1.21
Shares Outstanding
89.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CELLDEX THERAPEUTICS INC (CLDX)

Related News

No related news articles were found.

celldex therapeutics inc (CLDX) Related Businessweek News

No Related Businessweek News Found

celldex therapeutics inc (CLDX) Details

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. Its lead drug candidates include rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma and a Phase II study for the treatment of recurrent glioblastoma; and Glembatumumab vedotin (CDX-011) is a targeted antibody-drug conjugate in a randomized study for the treatment of triple negative breast cancer. The company also has various earlier stage drug candidates in clinical development, including varlilumab (CDX-1127), a fully human therapeutic monoclonal antibody for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-1401, a targeted immunotherapeutic aimed at antigen presenting cells for cancer indications. Its preclinical product candidate includes CDX-014, a human monoclonal antibody-drug conjugate that targets TIM-1, a molecule that is expressed on renal and ovarian cancers with minimal expression in normal tissues. The company has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; Duke University Brain Tumor Cancer Center; Ludwig Institute for Cancer Research; University of Southampton; Amgen Inc.; Amgen Fremont; Seattle Genetics, Inc.; and Bristol-Myers Squibb Company. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

120 Employees
Last Reported Date: 03/3/14

celldex therapeutics inc (CLDX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $871.4K
Founder, Chief Scientific Officer and Executi...
Total Annual Compensation: $553.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $437.7K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $589.4K
Chief Business Officer and Senior Vice Presid...
Total Annual Compensation: $411.7K
Compensation as of Fiscal Year 2013.

celldex therapeutics inc (CLDX) Key Developments

Celldex Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Celldex Therapeutics, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenue of $0.592 million compared to $0.097 million a year ago. Operating loss was $28.459 million against $18.658 million a year ago. Net loss was $28.274 million or $0.32 per basic and diluted share compared to $19.016 million or $0.24 per basic and diluted share a year ago. The increase in revenue was primarily due to clinical trial collaboration with BMS and research and development agreement with Rockefeller. For the six months, the company reported total revenue of $1.008 million compared to $2.511 million a year ago. Operating loss was $60.037 million against $36.059 million a year ago. Net loss was $58.177 million or $0.65 per basic and diluted share compared to $36.348 million or $0.47 per basic and diluted share a year ago. The decrease in revenue was primarily due to the decrease in Rotarix(R) royalty revenue.

Celldex Therapeutics, Inc. Announces Executive Promotions

Celldex Therapeutics, Inc. announced three promotions in the Company's clinical and research departments: Tibor Keler, PhD promoted to Executive Vice President and Chief Scientific Officer; Thomas Davis, MD promoted to Executive Vice President and Chief Medical Officer; and Elizabeth Crowley promoted to Senior Vice President, Product Development. Dr. Keler is a founder of Celldex and most recently served as the company's Senior Vice President and Chief Scientific Officer. Most recently Dr. Davis served as Senior Vice President and Chief Medical Officer. Prior to that, he was Chief Medical Officer at GenVec and Senior Director of Clinical Science at Medarex. Ms. Crowley joined Celldex in 2009 as Vice President, Clinical Development. Prior to that, she held several senior level roles at CuraGen Corporation, most recently serving as the Vice President of Development Operations.

Celldex Therapeutics, Inc. to Report Q2, 2014 Results on Aug 06, 2014

Celldex Therapeutics, Inc. announced that they will report Q2, 2014 results After-Market on Aug 06, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLDX:US $15.91 USD +0.17

CLDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $3.88 USD +0.15
Bavarian Nordic A/S kr111.00 DKK -1.00
Genocea Biosciences Inc $12.81 USD +0.46
MELA Sciences Inc $2.35 USD +0.04
ZIOPHARM Oncology Inc $3.23 USD +0.08
View Industry Companies
 

Industry Analysis

CLDX

Industry Average

Valuation CLDX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 545.1x
Price/Book 5.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 448.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLDEX THERAPEUTICS INC, please visit www.celldextherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.